MEDNAX Inc (NYSE:MD) – Investment analysts at Jefferies Financial Group cut their Q4 2019 earnings per share estimates for shares of MEDNAX in a report issued on Wednesday, January 22nd, Zacks Investment Research reports. Jefferies Financial Group analyst J. Plagman now forecasts that the company will post earnings of $0.85 per share for the quarter, down from their prior estimate of $0.87. Jefferies Financial Group also issued estimates for MEDNAX’s Q1 2020 earnings at $0.57 EPS, Q2 2020 earnings at $0.82 EPS, Q3 2020 earnings at $0.85 EPS and Q4 2020 earnings at $0.86 EPS.
A number of other equities analysts also recently issued reports on MD. UBS Group cut their price objective on shares of MEDNAX from $19.00 to $18.00 and set a “sell” rating on the stock in a report on Friday, October 18th. JPMorgan Chase & Co. lifted their target price on MEDNAX from $26.00 to $33.00 and gave the stock a “neutral” rating in a research note on Friday, December 20th. SunTrust Banks lifted their target price on MEDNAX from $27.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. TheStreet cut MEDNAX from a “c-” rating to a “d” rating in a research note on Friday, November 1st. Finally, Mizuho set a $25.00 target price on MEDNAX and gave the stock a “hold” rating in a research note on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $27.33.
MD opened at $25.58 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 1.93 and a quick ratio of 1.93. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -1.46, a P/E/G ratio of 0.98 and a beta of 0.84. The firm’s fifty day moving average price is $26.66 and its two-hundred day moving average price is $24.36. MEDNAX has a 1 year low of $19.93 and a 1 year high of $37.41.
A number of institutional investors have recently made changes to their positions in the stock. Great Lakes Advisors LLC raised its stake in MEDNAX by 126.7% in the 4th quarter. Great Lakes Advisors LLC now owns 412,085 shares of the company’s stock valued at $11,452,000 after acquiring an additional 230,310 shares during the period. ETRADE Capital Management LLC bought a new stake in MEDNAX in the 4th quarter valued at about $567,000. Ontario Teachers Pension Plan Board bought a new stake in MEDNAX in the 4th quarter valued at about $484,000. Machina Capital S.A.S. raised its stake in MEDNAX by 101.6% in the 4th quarter. Machina Capital S.A.S. now owns 20,230 shares of the company’s stock valued at $562,000 after acquiring an additional 10,196 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in MEDNAX in the 4th quarter valued at about $1,002,000. Institutional investors and hedge funds own 91.20% of the company’s stock.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Read More: What is a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MEDNAX and related companies with MarketBeat.com’s FREE daily email newsletter.